GAD65 Autoantibody Immune Responses in Newly Diagnosed Type 1 Diabetes Children and in GADA Positive Children from General Population by Kivelä, Aleksi-Mikael
  
Aleksi-Mikael Kivelä 
GAD65 Autoantibody Immune Responses in 
Newly Diagnosed Type 1 Diabetes Children 
and in GADA Positive Children from General 
Population 
 
Metropolia University of Applied Sciences 
Bachelor of Laboratory Services 
Laboratory Sciences 
Thesis 
14.3.2018 
 Abstract 
  
Author 
Title 
 
 
Number of Pages 
Date 
Aleksi-Mikael Kivelä 
GAD65 Autoantibody Immune Responses in Newly Diagnosed 
Type 1 Diabetes Children and in GADA Positive Children from 
General Population 
31 pages + 1 appendices  
14.3.2018 
Degree Bachelor of Laboratory Services 
Degree Programme Laboratory Sciences 
Instructors 
 
Taina Härkönen, PhD, University of Helsinki 
Tiina Soininen, Senior Lecturer, Metropolia UAS 
 
Type 1 Diabetes is an autoimmune disease caused by the destruction of insulin secreting 
beta cells in pancreas. There are at least 50 potentially causal genes, but environmental 
factors act as the trigger. Before and after Type 1 Diabetes has developed, autoantibodies 
start appearing in the bloodstream, which could potentially predict the risk of developing 
the disease. The four major autoantibodies are: IAA, GADA, IA-2A and ZnT8A. 
 
The focus of this study was GADA and its epitopes: many healthy people with no risk of 
developing Type 1 Diabetes are GADA positive. Serum samples were analyzed for auto-
antibodies with N-truncated GADA (tGADA). The method used in quantitative analysis of 
antibodies was radiobinding assay (RBA). Samples used in this study were from newly-di-
agnosed Type 1 Diabetes subjects in Finnish Pediatric Diabetes Register and from the DI-
ABIMMUNE study 3–5-year-old children from the general population who were GADA pos-
itive. 
 
The aim of this study was to determine whether specificity of the assay can be improved 
without losing sensitivity when using tGADA. Secondary goals were to determine which 
epitopes are the focus of immune response in multipositive, T1D positive and only-GADA 
positive subjects. 
 
Correlation between GADA and tGADA assays was good (0.63–0.96). In all subjects, the 
immune response was directed towards M- and C-epitopes in those who were multiposi-
tive or T1D positive. Immune response against N-epitope was mostly found on subjects 
who were only-GADA positive and who were not multipositive or T1D positive. 
 
With RBA, tGADA (96–585) recognizes T1D positives as well as GADA (1–585), but 
tGADA is better at recognizing those children who are at risk of developing type 1 diabetes 
or multipositivity in the future, thus tGADA is more specific, since it leaves out those who 
are only N-epitope positive. N-epitope positivity does not seem to have any effect on the 
risk of developing multiple autoantibodies or T1D.  
Keywords T1D, GADA, tGADA, RBA, Autoantibodies, Epitopes 
 Tiivistelmä 
  
Tekijä 
Otsikko 
 
 
Sivumäärä 
Aika 
Aleksi-Mikael Kivelä 
GAD65 autovasta-aineiden immuunivasteet tyypin 1 
diabetekseen vastasairastuneilla lapsilla ja GADA positiivisilla 
lapsilla valtaväestöstä 
31 sivua + 1 liite 
14.3.2018 
Tutkinto Laboratorioanalytiikka (AMK) 
Tutkinto-ohjelma Laboratorioanalytiikka 
Ohjaajat 
 
Taina Härkönen, FT, Helsingin Yliopisto 
Tiina Soininen, Lehtori, Metropolia Ammattikorkeakoulu 
 
Tyypin 1 Diabetes on haiman insuliinia tuottavien beetasolujen tuhoutumisesta johtuva 
autoimmuunisairaus.  Ihmisestä on löydetty ainakin 50 potentiaalisesti kausaalista geeniä, 
mutta ympäristölliset syyt toimivat autoimmuunivasteen laukaisijana. Ennen tyypin 1 
diabeteksen puhkeamista ja sen jälkeen, vereen erittyy autovasta-aineita, jotka voivat 
mahdollisesti ennustaa sairastumisriskiä; näistä suurimmat ovat IAA, GADA, IA-2A ja 
ZnT8A. Tutkimuksen kohteena oli erityisesti GADA ja sen epitoopit: monilta terveiltä 
ihmisiltä on löydetty GAD vasta-aineita verestä ilman, että heillä on riskiä sairastua tyypin 
1 diabetekseen. 
 
Tutkimuksen tarkoituksena oli selvittää, pystytäänkö menetelmän spesifisyyttä 
parantamaan käyttämällä N-leikattua GADA:a (tGADA) menettämättä sensitiivisyyttä. 
Toissijaisena tarkoituksena oli tutkia mitkä epitoopit ovat immuunivasteen kohteena 
multipositiivisilla, diabetekseen sairastuneilla ja vain GADA positiivisilla. Näyteseerumeista 
analysoitiin autovasta-aineiden vasteet käyttämällä N-leikattua GADA:a. Autovasta-
aineiden kvantitatiivisessa analyysissä käytettiin radiobinding menetelmää. 
Tutkimusaineistona käytettiin näyteseerumeita vastasairastuneilta lapsilta Suomen Lasten 
Diabetesrekisteristä ja DIABIMMUNE-tutkimuksessa 3–5 vuotiailta lapsilta kerättyjä 
GADA-positiivisia näytteitä, jotka olivat yleisestä väestöstä. 
 
Korrelaatio GADA ja tGADA menetelmien välillä oli hyvä (0.63–0.96). Kummassakin 
aineistossa immuunivaste kohdistui M- ja C-epitooppeja vastaan diabetekseen 
sairastuneilla ja multipositiivisilla. Vasteet N-epitooppia kohtaan esiintyivät lähinnä GADA-
positiivisilla potilailla, jotka eivät olleet multipositiivisia, eivätkä diabeetikoita. 
 
RBA menetelmällä tGADA (96–585) tunnistaa diabetekseen sairastuneet yhtä hyvin kuin 
GADA (1–585), mutta tGADA on parempi tunnistamaan riskilapset eli ne lapset, joilla on 
vaarana tulevaisuudessa muodostaa useita autovasta-aineita tai sairastua tyypin 1 
diabetekseen. tGADA on siis spesifisempi, sillä se jättää pois vain N-epitooppi positiiviset. 
N-epitooppi positiivisuudella ei näyttäisi olevan vaikutusta sairastumisvaaraan tai useiden 
autovasta-aineiden kehittymiseen. 
Avainsanat T1D, tGADA, GADA, RBA, Autovasta-aineet, Epitoopit 
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1 Introduction 
 
Type 1 Diabetes, an autoimmune disease, is characterized by immune-mediated re-
sponse against islets of Langerhans, eventually leading to insulin deficiency. During the 
pre-diabetic period, autoantibodies against pancreatic beta cell antigens appear in circu-
lation [1]. Type 1 Diabetes is usually diagnosed in childhood and adolescence and re-
mains as one of the most common autoimmune diseases in that age group. The HLA 
antigen II confers most of the genetic susceptibility, but there are at least 49 other genes 
that act as potential triggers [2]. The true cause of type 1 diabetes is unknown, but both 
viral and chemical, as well as environmental causes have been suggested and it could 
be triggered by a combination of two or more [1]. 
 
Pancreatic beta-cell antigens are the targets of immune response in type 1 diabetes. The 
most important autoantibodies that act as biomarkers for the disease are islet cell anti-
bodies (ICA), insulin autoantibodies (IAA), glutamic acid decarboxylase autoantibody 
(GADA), islet antigen-2 autoantibodies (IA-2A), zinc transporter 8 autoantibodies 
(ZnT8A). Appearance of GADA often means that the subject eventually develops type 1 
diabetes. However, depending on which GAD epitope the autoantibodies are directed 
against, the risk may be non-existent [3.] 
 
In Finland, over 60 cases of type 1 diabetes per 100 000 people are diagnosed annually. 
The study of type 1 diabetes is important because the disease increases risk for cardio-
vascular events, such as myocardial infarction, and the outcome is less-favorable when 
compared to non-diabetic patients. The risk for microvascular and other macrovascular 
complications is also higher in individuals with type 1 diabetes [1.] 
 
The main goal of the study was to determine, whether specificity of GADA assays can 
be improved without losing sensitivity when using N-terminally truncated GAD65 (tGAD). 
The secondary goals were to see which epitopes are focus of the immune response in 
type 1 progressors, multiantibody positive and single GADA positive subjects, and 
whether the results correlate with previous studies done on this subject.  
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2 Type 1 Diabetes 
 
Type 1 Diabetes (T1D) is an autoimmune disease where loss of insulin-producing pan-
creatic beta cells leads to hyperglycemia. It is usually diagnosed in childhood and ado-
lescence, but also increasingly in adults [1; 2]. 
 
The steps from initiation to progression of beta cell destruction are still unclear, but it is 
believed that beta-cell autoantigens are processed by antigen presenting cells (B cells, 
macrophages, dendritic cells) and presented to naive T cells in pancreatic lymph nodes, 
followed by generation of autoreactive T cells (both CD4+ and CD8+) [1; 25]. 
 
In pre-diabetic phase, the disease is characterized by the appearance of autoantibodies 
produced by B cells in the bloodstream of the patient. These are directed against one or 
more of the following: ICA, IAA, GADA, IA-2A. The autoantibodies act as a reproducible 
biomarker during the development of the disease; the destruction of the β-cells is caused 
by autoreactive CD8+ T cells [1]. 
 
Measurement of autoantibodies can also be used to distinguish T1D from other forms of 
diabetes. There are many hypotheses of how beta-cell autoimmunity is initiated, but none 
of them alone are responsible for the development of the disease. Both genetic predis-
position and environmental factors are thought to affect both the initiation and the rate of 
disease progression. One promising avenue of study has been the impact of viral infec-
tions in pathogenesis, specifically Enteroviruses [1; 2.] 
 
It has been proposed that the development of type 1 diabetes happens in three stages. 
In the first stage, beta-cell autoimmunity is initiated, and the autoantibodies appear in 
circulation. At this point the beta-cell mass remains high and none of the usual symptoms 
of the disease have manifested. In stage two, there is a change in blood sugar regulation 
and the beta-cell mass starts to decrease, even though the disease itself remains asymp-
tomatic. In the third stage, the beta-cell mass has dropped so low that it leads to insulin 
deficiency, and the usual symptoms of type 1 diabetes start appearing (Figure 1.) [4.] 
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Figure 1. Staging of type 1 diabetes [4] 
 
2.1 Genetics 
 
There are at least 50 potentially causal disease genes associated with type 1 diabetes 
and 58 genomic regions show genome-wide evidence for association. The human leu-
kocyte antigen (HLA) gene complex, or a group of genes, confers the largest contribution 
(about 50%) to the total genetic risk of developing type 1 diabetes. 
 
The appearances of islet autoantibodies are known to be associated with HLA-DR-DQ 
haplotypes. The patients with HLA-DR4-DQ8 haplotype had usually insulin as the first 
autoantibody, whereas those homozygous with HLA-DR3-DQ2 had GADA as the first 
autoantibody. Other HLA class II molecules, HLA-DRB3; HLA-DRB4 and HLA-DRB5, 
could be contributing to the initial triggering of beta-cell autoimmunity and type 1 diabe-
tes. In children younger than 12 years, HLA class II haplotypes DRB1*1501 and 
DQA1*0102-DQB1*0602 confer disease resistance against type 1 diabetes [4.] Genetic 
polymorphisms in INS and PTPN22 genes respectively contribute to the genetic cause 
of diabetes and to the risk of developing insulin autoantibodies as the first islet autoanti-
body. Genetics are an important factor with the development and predilection of type 1 
diabetes, but environmental factors are the triggers for the disease [2]. 
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2.2 Environmental Factors  
 
Type 1 diabetes is thought to have many environmental triggers, from certain viruses 
and diet to hygiene and route of neonatal delivery, antibiotics and host microbiome [4; 
5]. Enteroviruses have been suggested as potential triggers in type 1 diabetes and latent 
autoimmune diabetes of adults (LADA), specifically the Coxsackie -family of viruses [6]. 
Some epidemiological and immunological studies indicate that the early introduction of   
complex proteins early in infancy may increase beta-cell autoimmunity and diabetes risk 
[7; 8]. Researchers have studied the effect of removing bovine insulin from cow’s milk 
formula or the use of hydrolysed infant formula in beta-cell autoimmunity. Pilot studies 
indicated that the use of bovine insulin free milk or hydrolysed milk formula reduced the 
incidence of autoantibodies in children with genetic risk [7; 8]. However, an international 
clinical trial with 2159 newborn infants showed that neither the beta-cell autoimmunity 
nor the incidence of type 1 diabetes was reduced among children who were weaned to 
hydrolysed formula when compared to conventional formula [9; 10].  
 
The DIABIMMUNE study aims at assessing the role of environmental factors, especially 
the role of hygiene in the pathogenesis of type 1 diabetes, celiac disease and allergies. 
According to the hygiene hypothesis, early exposure to specific micro-organisms and 
allergens in infancy is beneficial to developing immune system and accordingly confers 
protection against many allergic and autoimmune diseases. Indeed, there is a regional 
difference in the prevalence of type 1 diabetes in Finland, Estonia and Russian Karelia, 
even though the genetic background between these regions is relatively similar [11]. 
 
The difference is significant: type 1 diabetes is most prevalent in Finland, where >60 
cases per 100 000 people are diagnosed annually, compared to Estonia where about 10 
cases per 100 000 people and in Russian Karelia less than 10 cases per 100 000 people 
are diagnosed annually [12]. The hypothesized reason for such major differences in num-
bers is thought to be the difference in childhood hygiene, where children exposed to a 
larger number of bacteria and allergens in childhood have a smaller risk of developing 
type 1 diabetes and other autoimmune diseases [13]. 
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The DIABIMMUNE studies indicate that diversity of gut microbiome decreases in T1D 
progressors after autoantibody seroconversion [5]. The studies also indicated the pre-
dominance of Bacteroides species, low immune stimulators, in Finnish and Estonian chil-
dren, while they are low in abundance in Russian Karelian children [13]. 
2.3 Autoantibodies 
 
The appearance of autoantibodies against islet cell antigens is the first easily detectable 
sign of a possible beta cell autoimmunity. In young children the insulin autoantibodies 
are often the first ones to appear, in contrast to adult diabetics who usually display 
GAD65 or IA-2 autoantibody positivity when diagnosed [27, p. 383, Figure 2]. Testing 
positive for multiple autoantibodies is often indicative of an increased risk of progression 
to clinical type 1 diabetes. A study by Knip M. et al. [14] found that the highest positive 
predictive value (PPV) of 91.7% was connected to recurring positivity with IAA and ICA, 
with PPV decreasing as positivity for antibodies increased: testing positive for all four 
antibodies yielded a PPV of 55.7%, however it also yielded the highest disease sensitivity 
(54.4%) [14]. 
2.3.1 Islet Cell Autoantibodies 
 
Islet cell autoantibodies (ICA) against pancreatic islets were first detected by Botazzo et 
al. in 1974. This discovery led to metabolic studies of islet function and to the modelling 
of progressive disease stages in type 1 diabetes by George Eisenbarth in 1986 [2]. 
These autoantibodies are detected with immunofluorescence using pancreatic tissue 
from organ donors in blood group 0 as substrate. Islet cell autoantibodies consist from a 
heterogenous group of autoantibodies including IA-2A, GADA and ZnT8A. Circulating 
IA-2A levels, followed by ZnT8A correlate strongest with ICA titers in the blood, whereas 
the correlation was weaker between GADA and ICA titers. In general, ICA stain all islet 
cells but restricted or beta cell specific autoantibodies have also been found. Restricted 
autoantibodies have not been found to predict type 1 diabetes, unlike non-restricted au-
toantibodies [14.] 
2.3.2 Insulin 
 
Insulin is a protein expressed almost exclusively in the pancreas, specifically in pancre-
atic beta cells. It is used to regulate glucose levels in human blood and lack of insulin 
and insulin production is what leads to type 1 diabetes. Some extra-pancreatic expres-
sion of insulin is in thymic medullary epithelial cells at both mRNA and protein levels. 
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The insulin autoantibody (IAA) epitopes have been identified in both the A chain and the 
B chain of insulin, within residues 8–13 and 28–30 respectively [3]. IAA are the least 
frequent autoantibody in newly diagnosed type 1 diabetes children, with only 44.8% 
showing positivity. However, IAA often appears as the first autoantibody in genetically 
susceptible infants [14.] 
2.3.3 Glutamic Acid Decarboxylase 
 
Glutamic acid decarboxylase (GAD65) is an enzyme in the biosynthesis of gamma-ami-
nobutyric acid (GABA), which is an important neurotransmitter in the central nervous 
system. Some diabetic patients can also develop antibodies against GAD67, the homo-
logue of GAD65. GAD65 consists of the amino (N), middle (M) and carboxy (C)-terminal 
regions with a length of 65 kDa (Figure 2). GAD65 is not solely expressed in the beta 
cells of pancreas but are present in several tissues where GABAergic systems exist, 
such as neurons of the nervous system [3.]  
 
 
Figure 2. Structure of GAD65 [15]  
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Glutamic acid decarboxylase autoantibodies (GADA) have been implicated in several 
other autoimmune diseases of the central nervous system such as stiff person syndrome, 
Batten disease and cerebral ataxia. GADA are also common in patients with autoimmune 
polyendocrinopathy and immunodysregulation polyendocrinopathy enteropathy X-linked 
(IPEX) syndrome. While these patients frequently develop type 1 diabetes, the autoanti-
bodies against GAD can be present even in the absence of T1D. Immune response 
against GAD is most common in adult-onset of type 1 diabetes, but it is also common in 
children, appearing often between ages 2 and 3 years. Accordingly, GAD is thought to 
be one of the primary targets in autoimmune process of T1D [3; 14.] 
2.3.4 Islet Antigen 2 
 
Islet Antigen 2 (IA-2) is a protein tyrosine phosphatase (PTP) like protein inherent to the 
membrane of secretory granules. It is not expressed exclusively in the pancreatic beta 
cells; it is also present in several neuroendocrine cells. The immune response is directed 
against epitopes in the cytoplasmic JM domain and epitopes in the PTP-like domains [3]. 
The biological role of IA-2 is not entirely known: it can influence insulin secretion, secre-
tory granules biogenesis and homeostasis as well as beta cell expansion, but no ligand 
that would bind it to ectodomain has been identified. Neither has the PTP-like domain 
any phosphatase activity [3]. 
 
IA-2 autoantibodies are common autoantibodies in type 1 diabetes diagnosed children, 
with a prevalence of about 76 % [3; 14]. It is usually thought that the autoimmune process 
has already progressed far when IA-2 autoantibodies appear, but IA-2A can also be the 
first autoantibody to appear 
2.3.5 Zinc Transporter Protein 8 
 
Zinc Transporter Protein 8 (ZnT8) is a transmembrane protein that regulates cellular zinc 
content. It has six transmembrane domains and a histidine-rich loop between domains 
IV and V. ZnT8 is critical for the maintenance of stored insulin, because it accumulates 
zinc into the secretory granules. The protein is expressed almost exclusively in pancre-
atic islets, particularly in β cells, with low levels in α cells and possibly in the cells of the 
retina [3.] 
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The epitopes of ZnT8 are present in both the NH2 and COOH terminus. The immune 
response is almost completely directed against the COOH epitopes, with less than 10% 
of patients showing antibodies to the NH2 terminus. Some antibodies have been identi-
fied that are specific towards polymorphic variants of arginine or tryptophan at amino 
acid residue 325 in COOH terminus. 
 
While ZnT8 autoantibodies are not as frequent as the other autoantibodies, still over 60% 
of type 1 diabetes diagnosed children are ZnT8A positive [3; 14.] 
3 Analysis of Type 1 Diabetes-Associated Autoantibodies 
 
3.1 Radiobinding Assay 
 
Radiobinding assay (RBA) is a method used in detection of antibodies against a specific 
antigen. The principle of autoantibody radiobinding assay is shown in Figure 3. The se-
rum samples are incubated with a labelled antigen, either 125-Iodine for IAA, or 35S-
methionine for GADA, ZnT8A and IA-2. The immune complexes that form are precipi-
tated with a protein A Sepharose and the unbound antigen is washed with a buffer, using 
either centrifugation or filtration technique. RBA is relatively cheap, low volume method 
that can be used to analyse a large number of samples. The downsides are the use of 
radioactive material and the differences in sensitivity and specificity between laborato-
ries.  
 
According to the 2002–2016 Islet Autoantibody Standardization Program (IASP) the sen-
sitivities and specificities of the assays were: 42–62% and 92–99% for IAA, 64–90% and 
90–98% for GADA, 62–72% and 93–100% for IA-2A, 48–70% and 97–100% for ZnT8A. 
The IASP and DASP Workshop results and diagrams were taken from a summary table 
that was sent to the participating laboratories, these tables are not available for public 
viewing. The workshop results vary widely between laboratories, autoantibodies and as-
says. The purpose of the DASP and IASP Workshop diagrams and results is to show 
the sensitivities and specificities of the assays in a comparable form, when analysing 
different autoantibodies. 
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Figure 3. The radiobinding assay principle [26, p. 48] 
 
3.2 Enzyme-linked Immunosorbent Assays 
 
Enzyme-linked immunosorbent assays (ELISA) are a common immunogenicity method 
used in the analysis, identification and quantification of different antibodies and antigens. 
There are three methods used in immunogenicity assessment: Direct/Indirect ELISA, 
Bridging or “Sandwich” ELISA and Competitive ELISA. In direct ELISA assay an enzyme-
labelled anti-immunoglobulin conjugated to an enzyme or a small molecule, such as bi-
otin, is used to detect bound antibodies when plasma or serum samples are incubated 
with the immobilized antigen. The indirect method uses an antigen that is anchored using 
an immobilized capturing agent, such as streptavidin. The bridging ELISA uses the anti-
gen for both capturing and detection of the antibody: an antigen is bound to the bottom 
of the assay plates and after the sample is added, the conjugated antigen is added to 
produce a colour change. The competitive ELISA uses competitive binding between the 
antibodies: the sample is first incubated with the antigen and then washed so that un-
bound antibodies are removed (Figure 4.) 
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Figure 4. ELISA principles [18] 
 
In all methods, the final step is the addition of a substrate to produce a colour change; 
the sample is then quantified with spectrophotometry. It is possible to determine IA-2A, 
GADA and ZnT8A with commercial ELISA kits, but determining IAA with ELISA has not 
yet been successful. [16; 17.] The 2015 IASP workshop sensitivity and specificity values 
for ELISA (bridge): GADA 76–86% and 97–99%, IA-2A 58–68% and 96–100% (Figures 
5, 6 and 7). 
 
Figure 5. IASP 2015 workshop sensitivity vs. specificity for GADA. 
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Figure 6. IASP 2015 workshop sensitivity vs. specificity for IA-2A. 
 
 
Figure 7. IASP 2015 workshop sensitivity vs. specificity for ZnT8A. 
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3.3 Electrochemiluminescence 
 
Electrochemiluminescence (ECL) is a novel method used in the analysis of biological 
substances. It uses ruthenium-conjugated proteins instead of the common enzyme-con-
jugates. When a voltage is run through the sample, ruthenium ions undergo an oxidation-
reduction reaction when in the presence of tripropylamine which then generates an ECL 
reaction. In a study by Steck AK. et al.  [19] it was found that ECL could determine affinity 
to type 1 diabetes in those with a single antibody much more precisely than regular radi-
oimmunoassays and it could be used to assess the risk of developing the disease much 
earlier than usual. Sensitivity and specificity values for ECL in the 2015 IASP workshop 
were: GADA 78% and 96%, IA-2A 72% 98%, IAA 60% and 98% (Figures 5 and 8). [17; 
19]. 
 
 
Figure 8. IASP 2015 workshop sensitivity vs. specificity for IAA 
  
13 
 
  
4 Truncated GAD65 (96–585) and GAD65 N-, M- and C-Epitopes 
 
GAD autoantibodies are sensitive, widely used markers of islet autoimmunity and type 1 
diabetes, and are used in diagnosis and prediction of diabetes, and in recruitment to 
intervention studies [14]. GAD autoantibodies are, however, found also in many healthy 
subjects without increased risk of progression to diabetes [16; 23; 24]. Recent interna-
tional autoantibody standardization workshops have revealed that there are differences 
between RBA and ELISA in recognition of GAD in healthy control subjects. Further char-
acterization revealed that control sera which were positive by radiobinding assay, but 
negative by ELISA recognized N-terminal (amino acids 1–95) epitope of GAD65 protein 
[16]. Studies by Williams et al. [20] showed that specificity of GADA assay was more 
specific when N-terminally truncated GAD65 (96–585) was used, while the sensitivity in 
patients was the same with both labels.  It was suggested that truncated GAD65 should 
be used, especially when screening healthy family members for intervention trials [20]. 
 
It has been determined that the predilection to developing type 1 diabetes is related to 
an immune response against the epitopes in M- and C-terminals [22; 20]. Immune re-
sponse against N-terminal has a minimal impact: it leads to non-specific binding of the 
GAD65 autoantibodies, which is not relevant to the pathogenesis of type 1 diabetes [20]. 
In sibling studies, it was determined that, while the initial response was simultaneously 
directed against the M- and C-terminals of the molecule, in some cases it later spread to 
the N-terminal [20]. In a study on GAD65 epitopes by Hoppu et al. [21] it was found that 
the antibodies were most abundant towards the M-epitope (94%) followed by C-epitope 
(83%) in the initial samples in diabetic and unaffected subjects. In a follow-up the ratios 
remained the same, with highest response directed towards M-epitope, followed by C-
epitope. N-epitope response remained low (22%) in both study groups [21]. 
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5 Materials and Methods 
 
5.1 Subjects 
The Finnish Pediatric Diabetes Register 
The Finnish Pediatric Diabetes Register has been collecting data and blood samples 
from children with type 1 diabetes before the age of 16 years and their first-degree family 
members since June 2002. By 2016 there were over 8000 children with type 1 diabetes 
and over 13000 family members in the registry and it covers over 90% of the children 
with type 1 diabetes in Finland. In total, 101 samples with varying concentrations of au-
toantibodies were selected, concentrating on GAD65 autoantibodies near the cut off. 
Median age of the subjects was 9.15 years, with minimum age being 1.3 years and max-
imum 16.2 years. The samples were previously analyzed for ICA, IAA, GADA, IA-2A and 
ZnT8A and were now assayed for truncated GAD65 (96–585) autoantibodies and 
GAD65 N-, M- and C-epitope specificities. 
 
DIABIMMUNE 
 
The DIABIMMUNE study aimed at assessing the role of environmental factors in patho-
genesis of type 1 diabetes, allergies and other immune-mediated diseases, focusing on 
the role of hygiene. Samples were collected from Finland, Estonia and Russian Karelia 
into two cohorts: the birth cohort and the young children cohort (YCC). Children in the 
YCC were recruited from the general population at the age of three years (36 months) 
and followed-up until the age of five (60 months). The children who were positive either 
for type 1 diabetes autoantibodies or allergen specific antibodies were invited also to 
four-year (48 months) visit. In total, there were over 3600 children in the YCC and the 
samples were collected to analyze type 1 diabetes, celiac disease, autoantibodies, aller-
gies, T cell regulatory function, infections, epigenetics and gut microbiome. The samples 
selected for this study were from subjects in the YCC who tested positive for GADA at 
some point during DIABIMMUNE.  
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These samples were used to answer two questions: can specificity be improved without 
losing sensitivity with N-truncated GADA and does epitope specificity differ in children 
whose immune response does not spread from GADA to other antigens compared to 
those whose autoimmune response spread to other antigens, and possibly progress to 
type 1 diabetes. In total, 203 samples from 83 subjects were analyzed. 
5.2 Methods 
All samples were analysed for GAD65 antibodies, truncated GAD65 (96–585) and GAD-
epitope autoantibodies with a radiobinding assay, as described previously [21]. Three 
different GAD65/GAD67 chimeras were used to analyse epitope-specific antibodies: 1. 
(GAD65 1–95/GAD67 102–593) to measure amino-terminal antibodies (N-epitope auto-
antibodies), 2. (GAD65 1–101/GAD65 96–444/GAD67 453–593) to determine the middle 
PLP binding domain specific autoantibodies (M-epitope autoantibodies) and 3. (GAD67 
1–453/GAD65 445–585) to determine carboxy-terminal autoantibodies (C-epitope auto-
antibodies). The results were expressed in relative units (RU) based on a standard curve 
constructed from a dilution of a pool of highly positive samples. The cut-off limit for anti-
body positivity (5.36 RU) was set at the 99th percentile of 373 non-diabetic Finnish chil-
dren and adolescents. The cut-off limit for positivity for GAD epitopes was set at the 99th 
percentile in 104 non-diabetic young Finnish subjects and were 0.86 RU for N-epitope, 
1.51 RU for M-epitope and 1.59 RU for C-epitope. 
 
All analyses followed the following procedure: 2 μl of samples, standards and controls 
were incubated at +4 ˚C overnight in 96-well plates with shaking (300 RPM) with 20 000 
CPM of 35S-labelled antigen diluted in 50 μl of TBST buffer (50 mM Tris, 150 mM NaCl, 
0.1% Tween-20 (Amresco Inc., Ohio, USA), pH 7.4). 35S-methionine (CAT NEG709A; 
Perkin Elmer, USA) labelled antigens were produced with TNTCoupled Reticulocyte Ly-
sate system (CAT L1170; Promega, Madison, WI, USA). 
 
After incubation, Protein A Sepharose CL-4B (PAS; 17-0963, GE Healthcare) + TBST 
solution was prepared in to a conical tube, with a concentration of 10 μl of PAS per well. 
Prior to making the solution, PAS was washed by centrifuging the solution with at least 
4x its volume of TBST in 1000 RPM for 5 minutes. After centrifuging, the supernatant 
was aspirated. The required volume of TBST was calculated for 40 μl per well plus the 
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volume of ethanol lost during aspiration, roughly 20%. The PAS solution was then pipet-
ted on the plates with the samples. Plates were then incubated in a mixer for a minimum 
of 1 hour in +4 ˚C and 1000 RPM. After incubation, the plates were washed with TBST, 
centrifuged for 3 minutes in +4 ˚C and 2000 RPM, after centrifugation the supernatant 
was aspirated. This process was repeated for 5 times, then the plates were incubated 
for 30 minutes to 1 hour in +4 ˚C and 1000 RPM. 
 
Afterwards, the samples were transferred on to the liquid scintillation plates with the scin-
tillation liquid (Optiphase Supermix; Perkin Elmer, USA; CAT 1200-439 for 1x5l) and then 
the plates were incubated while protected from light in room temperature and 900 RPM. 
Finally, the bound activity on the plates was measured by using a liquid scintillation coun-
ter (1450 MicroBeta Trilux; Perkin Elmer Life Sciences Wallac, Turku, Finland). The re-
sults were calculated using a MultiCalc software (Perkin Elmer Life Sciences Wallac) 
and compared to a standard curve constructed from serial dilutions of nine highly positive 
standard samples and one negative sample. 
5.3 Data Analysis 
 
The data of Diabetes Register and the DIABIMMUNE were not normally distributed (His-
tograms shown in Appendix 1.) Differences in the frequencies of autoantibodies were 
tested with Chi-squared statistics. The Mann-Whitney U-test was used to compare RU 
levels of autoantibodies. Correlations were analysed using the Spearman’s non-para-
metric correlation. The statistical analyses were performed with IBM SPSS Statistics, 
version 25. For all analyses, P value of 0.05 was considered significant. Venn diagrams 
were drawn with http://bioinformatics.psb.ugent.be/webtools/Venn/ and edited with 
InkScape software version 0.92.2, diagrams were drawn with Microsoft Excel 2015. 
6 Results  
 
6.1 Children with Newly Diagnosed Type 1 Diabetes 
 
Type 1 diabetes children diagnosed under 16 years of age with varying concentrations 
of GAD65 autoantibodies were selected for this study and analysed for truncated GAD65 
(96–585) autoantibodies. 
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There was good correlation between the levels of GADA (1–585) and GADA (96–585) (r 
= 0.96, P < 0.00; Figure 9A). The autoantibody levels and frequencies near the cut-off 
value (5.36 RU) are represented in Figure 9B.  
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Figure 9. (A) Correlation diagram of GADA (1–585) and GADA (96–585) results for 101 newly diag-
nosed patients. Low positive GADA results (<=10 RU) and the corresponding truncated GADA results 
(B) show that altogether two more type 1 diabetic patients tested positive for tGAD (96–585) com-
pared to GADA (1–585). Threshold for both assays is 5.36 and is represented with dotted lines. Re-
sults over the cut-off value are shown by red dots. 
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Out of 101 subjects, 63 (62%) were positive for GADA (1–585) and 65 (64%) were pos-
itive for GADA (96–585). Sixty (59%) patients showed positivity for both GADA (1–585) 
and GADA (96–585) (Figure 10A). There was no statistical difference in frequency of 
positivity between assays (P = 0.77). Majority of the subjects were positive only for M-
epitope (12.7%), with N-epitope (5.9%) and C-epitope (5.9%) showing almost equal 
numbers of positives (Figure 10B). Out of 63 GADA (1–585) positives, 11 subjects (17%) 
were positive for N-epitope, 25 subjects (40%) were positive for M-epitope, and 18 sub-
jects (29%) were positive for C-epitope. While majority of the subjects showed positivity 
for both M- and C-epitopes; 4 subjects (3.9%) showed positivity for all three epitopes, 
only 1 subject (0.98%) showed positivity for both N- and C-epitopes and no subjects 
were positive for both M- and N-epitopes (Figure 10B) nor in the frequencies of autoan-
tibodies (P = 0.77). Twenty-eight (44%) subjects did not show positivity for any epitope 
and out of that group 2 subjects (3.1%) were negative for truncated GADA (96–585). 
 
 
A 
 
 
B 
 
Figure 10. Venn diagram showing the frequency of GADA and truncated GADA results (A) in newly 
diagnosed type 1 patients. Two more patients were found to be positive for tGADA (96–585) that for 
GADA (1–585), but the difference was not significant (P = 0.77). Venn diagram showing N-, M-, and 
C-epitope responses (B) in newly diagnosed type 1 diabetes patients 
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6.2 DIABIMMUNE Children 
 
Out of over 3600 DIABIMMUNE children (the YCC), 83 children were previously found 
to be GADA (1–585) positive in at least one sampling point (3, 4 and 5 years). All time 
points (202 samples) of these children were analysed for truncated GAD65 (96–585) 
autoantibodies. There was statistically significant correlation between GADA (1–585) 
and GADA (96–585) levels (r = 0.63, P < 0.001; Figure 11). There was, however, signif-
icant difference in frequencies of GADA (1–585) and tGADA (96–585) positivity (P < 
0.001). 
 
 
Figure 11. Correlation of GADA (1–585) and GADA (96–585) results in 202 serum samples from 83 
DIABIMMUNE children. Threshold for both assays is 5.36 RU and is shown in the diagram with dotted 
lines. 
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Out of 202 samples in 83 subjects, 120 (59%) were positive for GADA (1–585) and 82 
(41%) were positive for GADA (96–585). In total 60 samples out of 202 had discrepan-
cies in GADA and tGADA results. Those positive only for tGADA (11 samples) were all 
low positive (5.74 – 10.73 RU), as were most of solely GADA positive (49 samples). Out 
of 60 samples, 5 had autoantibody levels above 20 RU. Seventy-one (35%) samples 
showed positivity for both GADA (1–585) and GADA (96–585; Figure 12). GADA levels 
(1-585) were significantly higher than tGADA (96–585) levels P = 0.037. 
 
 
Figure 12. Venn diagram of GADA (1–585) and GADA (96–585) positive DIABIMMUNE subjects. 
 
Correlation between GADA (1–585) and GADA (96–585) results at 36 months of age is 
shown in Figure 13. When all samples are included in analysis, the correlation was sig-
nificant (r = 0.63, P < 0.001). It increased to 0.88 when GADA positive, but tGADA neg-
ative results (24) were abolished from the analysis. Correlation of GADA (1-585) and 
tGADA (96–585) was very good for multiple autoantibody positive and T1D patients (r = 
0.93) at 36 months, and excellent at 48 and 60 months of age (r = 0.97 and 0.99, respec-
tively).  
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The frequency of tGADA positivity was higher at 36 months of age in children who de-
veloped multiple autoantibodies during the follow-up period compared to only single-
GADA positive (78.9% vs 14.8%, P =< 0.001). 
 
Figure 13. Plot of GADA (1-585) and tGADA (96-585) results at 36 months of age. DIABIMMUNE chil-
dren, who progressed to type 1 diabetes are indicated in red points, those who developed multiple 
autoantibodies during the follow-up time, but have not progressed to diabetes are shown with green 
points. Black points represent children who are GADA and/or tGADA positive but have not developed 
other beta cell autoantibodies during the follow-up. Of these N-epitope positive samples are indi-
cated with purple points. The dotted lines represent the cut-off points for positive values (5.56 RU).  
 
Out of merely GADA (1–585) positive subjects, 12 (14%) were positive only at 36 
months, 1 (1%) was positive only at 48 months and 7 (8%) were positive only at 60 
months. Seven (8%) subjects were positive only at 36 and 48 months, 1 (1%) was posi-
tive at 48 and 60 months and none were positive at 36 and 60 months. Four (5%) sub-
jects were positive at all time points (Figure 14). 
 
 
 
Figure 14. Venn diagram of GADA (1–585) positives, but tGADA (96-585) negative samples at different 
ages.  
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Of 83 subjects at 36 months, 46 (55%) were positive for GADA (1–585), twenty-four 
(29%) were positive for GADA (96–585), seven (8%) were positive for N-epitope, 12 
(14%) were positive for M-epitope and 11 (13%) were positive for C-epitope. Out of 83 
subjects at 60 months, 46 subjects (55%) were positive for GADA (1–585), thirty-four 
subjects (41%) were positive for GADA (96–585), eleven subjects (13%) were positive 
for N-epitope, 19 subjects (83%) were positive for M-epitope and 12 subjects (14%) were 
positive for C-epitope (Figure 15). Of 120 GADA positive samples, 57 were negative for 
all epitope antibodies. The majority of these (35 samples) had antibody level under 10 
RU (media 8.67, range 5.43-27.07).  
 
 
Figure 15.  Frequencies of GAD65 (1-585), truncated GAD65 (96-585) and N-, M- and C epitope anti-
bodies in the DIABIMMUNE children at the age of 36 and 60 months. 
 
Altogether six children have progressed to type 1 diabetes up to now. Serum sample 
was available from five children at the age of 36 months, and from six children at 48 and 
60 months of age. Twenty percent (20%) of these children were positive for N-epitope, 
60% were positive for M-epitope and 40% were positive for C-epitope at the age of 36 
months. At the age of 48 months, 17% were positive for N-epitope, 67% were positive 
for M-epitope and 33% were positive for C-epitope and 17% were positive for N-epitope, 
50% were positive for M-epitope and 17% were positive for C-epitope at the age of 60 
months (Figure 16A and Table 1). M-epitope was the most common among progressors, 
followed by C-epitope. N-epitope was positive only in one subject. Most subjects also 
showed positivity for multiple epitope and were multipositive (Table 1). The other anti-
bodies besides GADA were: IAA (3 subjects at 36 months, 2 at 48 months and 2 at 60 
months), IA-2A (4 subjects at 36 months and 5 at 48 and 60 months), ZnT8A (4 subjects 
at 36 and 48 months, 3 at 60 months) and ICA (5 subjects at 36 and 48 months, 4 at 60 
months; Table 1). 
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Figure 16. Frequencies of antibodies to N-terminal (green line), middle (M, blue line) and C-terminal 
parts of GAD65 protein at 36, 48 and 60 months of age in T1D progressors (A), multiple autoantibody 
positive (B) and single-GADA/tGADA positive children (C). 
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In total, 15 children developed multiple autoantibodies during the follow-up time. Out of 
14 samples at the age of 36 months, nine were GADA (1–585) positive and of those, 
seven (78%) were positive both for M- and C-epitopes; 8 were positive for multiple auto-
antibodies (Figure 16B, Table 1). Out of 8 samples at 48 months, 6 were GADA (1–585) 
positive and of those, 5 (83%) were positive for M-epitope and 4 (67%) were positive for 
C-epitope; 5 were multiple autoantibody positive (Figure 16B, Table 1). Out of 11 GADA 
(1–585) positive samples at 60 months, 9 (82%) were positive for M-epitope and 7 (64%) 
were positive for C-epitope. Seven subjects out of nine were positive for both M- and C- 
epitopes (Figure 16B and Table 1). No subject showed positivity for N-epitope at any 
point. The other antibodies recognized were: IAA (6 subjects at 36 months, 3 at 48 
months and 6 at 60 months), IA-2A (3 subjects at 36 months, 2 at 48 months and 2 at 60 
months), ZnT8A (5 subjects at 36 months, 4 at 48 months and 6 at 60 months) and ICA 
(6 subjects at 36 months, 4 at 48 months and 7 at 60 months; Table 1). 
 
Of 32 subjects positive for GADA (1-585) at 36 months, 8 were positive for tGADA (96-
585), but autoimmunity did not spread to other beta-cell antigens during the follow-up 
time. Those positive for any epitope are shown in Table 1 and Figure 16C. Out of 32 
children, 6 (19%) were positive for N-epitope and 1 (3%) was positive for both M- and C-
epitopes at the age of 36 months. Out of 26 samples at 48 months, 10 were positive for 
GADA (1–585), 7 were positive for tGADA, 5 (38%) were positive for N-epitope and 1 
(8%) was positive for both M- and C-epitopes. Of 24 samples at 60 months, 5 were 
positive for GADA (1–585), 4 were positive for tGADA, 3 (13%) were positive for N-
epitope, 2 (8%) were positive for C-epitope and no sample was positive for M-epitope 
(Figure 16C, Table 1). 
 
The proportions of epitope frequencies in different type 1 risk classes are shown in Figure 
17. Out of nineteen samples from eight children with protective HLA risk class 0, three 
samples (16%) were positive for N-epitope, 1 sample (5%) was positive for M-epitope 
and no samples had positivity for C-epitope. Of 89 samples from 36 subjects with pro-
tective/no risk HLA risk class 0/1, seventeen samples (19%) were positive for N-epitope, 
13 samples (15%) were positive for M-epitope and 12 samples (13%) were positive for 
C-epitope. In 25 samples from nine children with HLA risk class 1 (no risk), two samples 
(8%) were positive for N-epitope, 7 samples (28%) were positive for M-epitope and 2 
samples (8%) were positive for C-epitope. Out of 23 samples from nine children with 
HLA risk class 2 (slightly increased risk), two samples (9%) were positive for N-epitope, 
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5 samples (22%) were positive for M-epitope and 3 samples (13%) were positive for C-
epitope. 
 
Out of 44 samples from 18 children with moderate or high with HLA risk class 3 (17 
subjects) or 4 (one subject), three samples (7%) were positive for N-epitope, 12 samples 
(27%) were positive for M-epitope and 9 samples (20%) were positive for C-epitope (Fig-
ure 19). For further analysis, the children were divided to two HLA risk groups: group 1. 
protective or no risk genotypes (risk classes 0–1, 53 subjects) and 2. increased risk gen-
otypes (risk classes 2–4, 29 subjects). All samples from children were included to the 
analysis. There was no statistical difference in GADA (1–585) positivity between the 
groups (p=0.799), but tGADA (96–585) positivity was significantly more common in the 
increased risk group 2 (60% vs. 29.5%, P < 0.001). N-epitope positivity was more com-
mon in the group 1 than in the group 2 (17.1% vs 7.1%, P = 0.051), while the M- and C-
epitope positivity was more common in the increased risk group 2 (P = 0.028 and P = 
0.043). 
 
 
Figure 17. The proportions of epitope frequencies according to type 1 diabetes HLA risk class (0 = 
protective genotype, 0/1 = protective or no risk, 1 = no risk, 2 = slightly increased risk, 3 = moderate 
risk, 4 = high risk). 
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7 Discussion 
 
In a previous study on N-truncated GADA by Williams et al. [16] in 2015, the sensitivity 
between GADA (1–585) and GADA (96–585) was identical (80%) in recently diagnosed 
type 1 diabetes patients with excellent correlation between the two methods (r = 0.99, P 
< 0.001). We had chosen 101 newly diagnosed type 1 diabetic patients from The National 
Diabetes Register with varying concentrations of GAD65 autoantibodies, concentrating 
in samples near the cut-off value, and analysed them for N-terminally truncated GAD65 
(tGADA, 96-585) and N-, M-, C-epitope autoantibodies. The correlation between GADA 
and tGADA assays was very good (r = 0.96, P < 0.001) and there was no significant 
difference in positivity between assays (P = 0.77).  
 
However, GADA (96–585) assay recognised two more type 1 diabetic patients compared 
to GADA assay (Figure 10A). The three subjects which were positive for GADA (1–585) 
but negative for truncated GADA (96–585) were low GADA (1–585) positive (5.50–9.90 
RU; Figure 9B), and they were multiple autoantibody positive samples; these subjects 
would not have remained autoantibody negative. Out of the six newly diagnosed subjects 
who were only N-epitope positive, 4 were positive for both GADA (1–585) and tGADA 
(96–585), one was positive only for GADA and one was negative for both. Most probably 
the immune response was partly directed to GAD67, but this was not analyzed. Other-
wise, the epitope immune responses followed a similar trend established in a study by 
Hoppu et al. [21] where most of the immune response in progressors was directed to-
wards M- and C-epitopes. 
 
The correlation in DIABIMMUNE subjects was not as good, though still significant, when 
compared to the newly diagnosed type 1 diabetes subjects (r = 0.96 v. r = 0.63; Figures 
10A and 12). Correlation of GADA and tGADA in first degree relatives of type diabetes 
patients according to study by Williams et al. [16] was 0.96, although many sera in the 
study were also GADA positive, but tGADA negative. The reason for this could be that 
our DIABIMMUNE children represent general population, they are not selected for type 
1 diabetes risk genotypes. Correlation improved significantly when we analyzed T1D and 
multiple autoantibody positive subjects and abolished samples of merely GADA positive 
subjects (r = 0.93 at 36 months, r = 0.97 at 48 months and r = 0.99 at 60 months). There 
was significant difference in frequency of positive samples between GADA and tGADA 
assays (58.3% and 39.7%, P < 0.001) and in the autoantibody levels (P = 0.037). 
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The frequency of truncated GADA (96–585) was higher at 36 months of age in children 
who developed to multiple autoantibody positive during the follow-up time compared to 
single GADA positive children (P < 0.001), while the frequency was not significantly dif-
ferent for GADA (P = 0.13). This would indicate that tGADA predicts multipositivity and 
T1D better than GADA (1–585). This is in line with results by Williams et al. [16], who 
showed that autoantibodies to truncated GAD65 in first degree relatives are more closely 
associated with diabetes risk than autoantibodies against full-length GAD65. 
 
The epitope frequencies showed some variation between subjects: frequencies of M- 
and C-epitopes were much higher in multiple autoantibody positive subjects and in those 
who later progressed to type 1 diabetes, whereas subjects who were only GADA (1–585) 
positive showed autoantibody response only towards N-epitope. Almost none of the sub-
jects showed epitope spreading: in all cases, except two who showed epitope spreading 
towards the C-epitope, the immune response was simultaneous and did not later spread 
to other epitopes. However, the first samples were taken at the age of three years, and 
many subjects were already multipositive at that point, which means that we did not have 
access to samples at the earliest stage of beta cell immunity. Further, the last sample 
was taken at the age of five years, and possible further epitope spreading could not be 
analyzed. Our results followed a similar trend with those acquired in studies by Ron-
kainen et al. and Hoppu et al. [22; 21] where the immune response was focused on M-
epitope in progressors and multiple autoantibody positive subjects, followed by C-
epitope with very few showing positivity towards N-epitope.  
 
The epitope development in HLA phenotype risk classes showed that no type 1 diabetes 
risk -subjects (risk classes 0-1) had much higher frequencies of N-epitope, and elevated 
risk classes (risk classes 2-4) had increased frequencies of M- and C-epitopes. Trun-
cated GADA (96–585) positivity was also more common in HLA phenotype risk groups 
2–4, when compared to those with no risk/protective phenotype (p<0.001), while there 
was no significant difference in frequency of GADA positivity between risk groups 1 (risk 
classes 0–1) and 2 (risk classes 2–4) (P = 0.799). There is some discrepancy in epitope 
assay sensitivities; many subjects did not recognize any epitope or had values close to 
cut-off, but at the same time had high response to GADA. The epitope assays are either 
not sensitive enough, antigenic epitopes are hindered, and/or the responses were to-
wards GAD67, which our assays did not specify.  
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In conclusion, tGADA (96–585) assay recognizes T1D positives as well as GADA (1–
585) assay. In those children who are at a risk of developing multiple autoantibodies and 
T1D in the future, the tGADA assay is more specific since it leaves out those GADA 
positives whose immune response is only directed towards the N-epitope, which does 
not seem to be related to an increased risk of developing multipositivity or T1D. This is 
important especially when autoantibody positive participants are chosen for follow-up 
studies, such as intervention trials.  
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Histograms 
 
 
Figure 1 Histogram of GADA in total number of subjects, with distribution curve. 
 
 
Figure 2 Histogram of tGADA in total number of subjects, with distribution curve.
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Figure 3 Histogram of GADA in 36 month subjects, with distribution curve. 
 
Figure 4 Histogram of tGADA in 36 month subjects, with distribution curve.
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Figure 5 Histogram of GADA in 48 month subjects, with distribution curve. 
 
 
Figure 6 Histogram of tGADA in 48 month subjects, with distribution curve.
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Figure 7 Histogram of GADA in 60 month subjects, with distribution curve. 
 
Figure 8 Histogram of tGADA in 60 month subjects, with distribution curve. 
